Why the study?
Does upfront triple combination therapy improve functional capacity, hemodynamics, and survival in newly diagnosed patients with severe PAH?
Does upfront triple combination therapy improve functional capacity, hemodynamics, and survival in newly diagnosed patients with severe PAH?
Upfront triple combination therapy with IV epoprostenol, bosentan, and sildenafil in severe PAH provides significant clinical and hemodynamic improvements and may dramatically improve long-term survival compared to historical expectations.
Answers are grounded in this paper and cite their sources.
Upfront triple therapy may improve survival in severe PAH; hypothesis-generating and requires randomized confirmation.
Patients with severe pulmonary arterial hypertension (PAH) in New York Heart Association (NYHA) functional class (FC) III/IV have a poor prognosis, despite survival benefits being demonstrated with intravenous epoprostenol. In this pilot study, the efficacy and safety of a triple combination therapy regimen in patients with severe PAH was investigated. Data from newly diagnosed NYHA FC III/IV PAH patients (n=19) initiated on upfront triple combination therapy (intravenous epoprostenol, bosentan and sildenafil) were collected retrospectively from a prospective registry. Significant improvements in 6-min walk distance and haemodynamics were observed after 4 months' triple combination therapy in 18 patients (p<0.01); 17 patients had improved to NYHA FC I or II. One patient was not included in the month 4 assessment (due to an emergency lung transplant in month 3). At the final evaluation (mean ± sd 32 ± 19 months), all 18 patients had sustained clinical and haemodynamic improvement. Overall survival estimates for the triple combination cohort were 100% at 1, 2 and 3 years. Expected survival calculated from the French equation was 75% (95% CI 68-82%), 60% (95% CI 50-70%) and 49% (95% CI 38-60%) at 1, 2 and 3 years, respectively. This pilot study provides preliminary evidence of the long-term benefits of upfront triple combination therapy in patients with severe PAH.
No takes yet. Share an insight, caveat, or question.
Sitbon et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: